Please assess the completion status of the following clinical trial:

Trial Title: SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Kisumu County Hospital (KCH) adult primary care outpatient clinic attendees who screen positive for depression and/or PTSD~2. Ability to attend weekly IPT sessions/fluoxetine monitoring; (3) 18 years or older~Exclusion Criteria:~1. Cognitive dysfunction compromising ability to participate in IPT or accurately take fluoxetine (lack of orientation to person, place, time and situation)~2. acute suicidality requiring higher level of care~3. drug/alcohol use disorders requiring substance use treatment (AUDIT score of 8 or higher, DAST score of 3 or higher)~4. history of mania or requiring treatment for hypomania~5. Outside mental health treatment during the study treatment phases (any mental health treatment is allowed during follow-up phases and is recorded by study team).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interpersonal psychotherapy (Type: ACTIVE_COMPARATOR): IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
- fluoxetine (Type: ACTIVE_COMPARATOR): Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
- Fluoxetine after IPT (Type: ACTIVE_COMPARATOR): participants who do not remit from MDD and PTSD after treatment with IPT may be randomized to fluoxetine.
- IPT after fluoxetine (Type: ACTIVE_COMPARATOR): participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT.
- IPT + fluoxetine (Type: ACTIVE_COMPARATOR): participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT + fluoxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).